Science Editor Guo SY Language Editor Elsevier HK
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5392
Revised: April 13, 2005
Accepted: April 18, 2005
Published online: September 14, 2005
Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilateral, has been reported as a consequence of therapy with both non-pegylated and pegylated interferon (pegIFN) but is not a well-known adverse effect. We report a 45-year-old Caucasian woman who developed acute sensorineural hearing loss 2 mo after starting therapy with pegIFN-α 2b and ribavirin for the treatment of chronic HCV, genotype 1a. She did not report the hearing loss to the hepatitis clinic until 1 mo, later whereupon therapy was promptly discontinued. Although her serum alanine aminotransferase (ALT) normalized and her HCV-RNA became undetectable after 12 wk of pegIFN and ribavirin therapy, after discontinuation, her HCV-RNA became detectable with significant elevations of serum ALT. Four months after initial discontinuation, the patient re-commenced pegIFN and ribavirin combination therapy. After 44 of 48 wk of therapy, the patient’s liver biochemistry has normalized and the HCV-RNA is undetectable. She has not developed worsening of her hearing loss and hearing on the left-side is unaffected. Both patients and physicians should be aware that sensorineural hearing loss may occur with pegIFN therapy. Our experience suggests that re-institution of therapy is not always associated with further hearing impairment.
- Citation: Wong VK, Cheong-Lee C, Ford JAE, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy. World J Gastroenterol 2005; 11(34): 5392-5393
- URL: https://www.wjgnet.com/1007-9327/full/v11/i34/5392.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i34.5392
Chronic hepatitis C affects an estimated 300 million people worldwide, and within Canada, the prevalence is estimated between 0.75% and 1.0% of the general population. Treatment of hepatitis C virus (HCV) with interferon alpha (IFN-α) 2b and ribavirin therapy has been shown to be effective for many years now, with 41-47% of patients achieving a sustained virologic response[2-4]. With the current pegylated interferons (pegIFN) and ribavirin combination, overall sustained virologic response rates are reported to be 54-56%[5-7].
In spite of the current popularity of pegIFN and ribavirin therapy, many reported side-effects with standard IFN-α ARE also seen with pegIFN combination therapy. Flu-like symptoms such as fever, chills, muscle ache, nausea, vomiting, and fatigue are common side effects of treatment. Depression and related symptoms, such as anxiety, irritability, insomnia, and mental confusion, are not rare and may be significant in patients with a previous history. Common hematologic side effects that require monitoring include neutropenia and thrombocytopenia. Withdrawal rates in IFN-based combination studies due to side effects have ranged from 6% to 7%[4,8].
Although IFN-based therapy has been reported to affect any organ system, there have been occasional reports of sudden hearing loss while on IFN therapy[9-14]. We report a case of sudden unilateral hearing loss in a patient with HCV being treated with pegIFN and ribavirin combination therapy. The interesting aspect of our case is that pegIFN combination therapy was re-commenced at the patient’s request, despite the reservations of the hepatitis clinic staff.
A 45-year-old Caucasian woman with chronic hepatitis C (genotype 1a) acquired 25 years previously after the administration of Rh immune globulin, developed sudden onset of right sided hearing loss 2 mo after beginning therapy with pegIFN-α 2b at a dose of 1.5 μg/kg per week subcutaneously (100 μg/wk) and ribavirin 1 000 mg/d (Pegetron, Schering-Canada, Point-Clare QC, Canada). Before treatment, she had no evidence of decompensated liver disease and her serum alanine aminotransferase (ALT) was 132 U/L (upper limit of normal <36 U/L). At the time of her acute unilateral hearing loss, she had completed a course of antibiotics for an otis media in the left ear. The right-sided hearing loss was described as a sudden onset of deafness followed by marginal improvement such that the patient could hear a telephone dial tone and low-pitched sounds associated with tinnitus. She was seen in consultation by an otolaryngologist who reported that both middle ears were normal on visual inspection. Audiometric testing performed approximately 1 mo after the acute hearing loss was consistent with severe unilateral right-sided sensorineural loss. The patient’s pegIFN and ribavirin combination was discontinued immediately after the patient’s disclosure, to the hepatitis clinic, of the unilateral hearing impairment 1 mo after onset and 3 mo after commencement of antiviral therapy. Although her liver enzymes normalized and her HCV-RNA was undetectable (qualitative Cobas Amplicor HCV Test, Roche-Diagnostics Canada, Laval QC, Canada; lower detection limit = 10-15 IU/mL) after 12 wk of therapy, within 2 mo after discontinuation, the HCV-RNA was again detectable and her serum ALT flared to 267 U/L. Symptomatically, her unilateral hearing impairment did not improve further and she was advised not to continue with further anti-HCV therapy. Despite medical advice to the contrary, she re-commenced pegIFN and ribavirin therapy 4 mo after the initial discontinuation. After 44 wk of continued pegIFN and ribavirin therapy, her serum liver biochemistry has remained persistently normal (serum ALT = 16 U/L at mo 9 of therapy) and her HCV-RNA was undetectable at wk 24 of therapy. She has not had any left-sided hearing impairment although her right-sided hearing remains significantly impaired.
Side effects of IFN therapy for HCV have been well documented. However, acute sensorineural hearing loss is relatively rarely reported and not well known amongst those who provide treatment for HCV. Several cases were reported of sudden hearing loss in patients with HCV being treated with the previous standard of non-pegylated IFN-α2 therapy[10-13], presumably on the basis of focal small vessel vasculitis. One prospective study of 73 patients reported tinnitus and/or hearing loss in 32 patients (43.8%) during IFN therapy, and audiometry-documented sensorineural hearing loss in 27 cases (36.9%). These investigators reported that auditory disability frequently developed in the later stages of treatment, but most patients in this report recovered 7-14 d after the discontinuation of therapy.
More recently, Formann et al reported six cases of hearing loss that was associated with the current standard treatment of pegIFN and ribavirin combination therapy. In contrast to the study by Kanda et al these authors reported that hearing loss did not fully resolve after discontinuation of the therapy with pegIFN but also did not worsen on continued treatment. Our patient developed unilateral sensorineural hearing loss that was associated with pegIFN and ribavirin therapy. Therapy was discontinued but subsequently re-instituted at the patient’s request. Although the unilateral hearing loss was persistent, it did not worsen on re-treatment and bilateral hearing loss has not occurred.
We believe that sudden hearing loss as a side effect should be discussed, along with the other more commonly known side effects, with patients prior to being treated with standard or pegIFN therapy. We recommend that patients on interferon-based therapies should be monitored during treatment for changes in hearing perception. It remains possible that those who do develop sudden hearing loss can be continued on IFN therapy, if the risk-benefit ratio of treatment dictates.
|1.||Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Can J Public Health. 2000;91 Suppl 1:S18-21, S19-23. [PubMed] [Cited in This Article: ]|
|2.||McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 749] [Cited by in F6Publishing: 802] [Article Influence: 37.5] [Reference Citation Analysis (0)]|
|3.||Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C. Ran-domized trial of interferon alpha2b plus ribavirin for 48 wk or for 24 wk versus interferon alpha 2b plus placebo for 48 wk for treatment of chronic infection with hepatitis C virus. In-ternational Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432. [DOI] [Cited in This Article: ] [Cited by in Crossref: 1665] [Cited by in F6Publishing: 1804] [Article Influence: 69.4] [Reference Citation Analysis (0)]|
|4.||McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2504] [Cited by in F6Publishing: 2676] [Article Influence: 104.3] [Reference Citation Analysis (0)]|
|5.||Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4721] [Cited by in F6Publishing: 5012] [Article Influence: 224.8] [Reference Citation Analysis (0)]|
|6.||Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4833] [Cited by in F6Publishing: 5136] [Article Influence: 241.7] [Reference Citation Analysis (0)]|
|7.||Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2207] [Cited by in F6Publishing: 2347] [Article Influence: 122.6] [Reference Citation Analysis (0)]|
|8.||Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-87. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 446] [Cited by in F6Publishing: 474] [Article Influence: 18.6] [Reference Citation Analysis (0)]|
|9.||Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol. 2004;99:873-877. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis (0)]|
|10.||Obrebowski A, Walczak M, Swidziński P, Karlik M, Kurywczak-Grykiel K, Obrebowska-Karsznia Z. [Preliminary results of objective audiological assessment of children with hearing impairment selected in neonatal hearing screening]. Otolaryngol Pol. 2003;57:531-535. [PubMed] [Cited in This Article: ]|
|11.||Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol. 1998;112:962-963. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis (0)]|
|12.||Bailly F, Mattei A, Si Ahmed SN, Trepo C. [Sudden deafness induced by interferon-alpha in viral hepatitis C]. Gastroenterol Clin Biol. 1997;21:157-158. [PubMed] [Cited in This Article: ]|
|13.||Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283-291. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 295] [Cited by in F6Publishing: 242] [Article Influence: 11.8] [Reference Citation Analysis (0)]|